Navigation Links
Abbott Successfully Completes Tender Offer for Shares of Advanced Medical Optics
Date:2/25/2009

ABBOTT PARK, Ill., Feb. 25 /PRNewswire-FirstCall/ -- Abbott today announced the successful completion of the tender offer by its wholly owned subsidiary Rainforest Acquisition Inc. to purchase all of the outstanding shares of common stock of Advanced Medical Optics (AMO). The tender offer expired at midnight Eastern time on Tuesday, Feb. 24, 2009, and was not extended.

The depositary for the tender offer has advised Abbott that a total of approximately 56,395,914 shares of AMO common stock were validly tendered and not withdrawn (including approximately 6,657,258 shares subject to guaranteed delivery procedures). These shares, together with the shares beneficially owned by Abbott and its wholly owned subsidiaries, represent approximately 93.5 percent of AMO's outstanding shares of common stock, or approximately 83.1 percent on a fully diluted basis. All AMO shares that were validly tendered in the offer and not properly withdrawn have been accepted for payment.

As the final step of the acquisition process, Abbott intends to effect a short-form merger as promptly as practicable, without the need for a meeting of AMO stockholders. As a result of the merger, the remaining AMO stockholders (other than those who properly exercise dissenters' rights) will receive the same $22 per share price, without interest and subject to any required withholding taxes, that was paid in the tender offer. After the merger, AMO will be a wholly owned subsidiary of Abbott and AMO shares will cease to be traded on the New York Stock Exchange.

About Abbott

Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs approximately 69,000 people and markets its products in more than 130 countries.

Abbott's news releases and other information are available on the company's Web site at www.abbott.com.

-- Private Securities Litigation Reform Act of 1995 --

A Caution Concerning Forward-Looking Statements

Some statements in this news release may be forward-looking statements for the purposes of the Private Securities Litigation Reform Act of 1995. We caution that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated. Economic, competitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1A, "Risk Factors," to our Annual Report on Securities and Exchange Commission Form 10-K for the year ended Dec. 31, 2008, and are incorporated by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments.


'/>"/>
SOURCE Abbott
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Abbott Receives European Commission Clearance on Acquisition of Advanced Medical Optics
2. Abbott Receives FDA Clearance for New CELL-DYN(R) Emerald(TM) Hematology Instrument
3. Abbott Acquisition of Advanced Medical Optics Clears U.S. Antitrust Review
4. Fujirebio Diagnostics and Abbott Agree To Develop New Ovarian Cancer Test for Abbotts Architect(R) Analyzers
5. Abbott to Commence Tender Offer on Jan. 27 for All Outstanding Shares of Advanced Medical Optics, Inc.
6. Abbott Reports Double-Digit Sales and Earnings Growth in Fourth Quarter; Confirms Strong Outlook for 2009 Earnings
7. Abbott Opens New Pharmaceutical Research Laboratory in Singapore
8. Abbott Nutrition Announces Voluntary Recall of ZonePerfect(R) Chocolate Peanut Butter Bars, ZonePerfect(R) Peanut Toffee Bars and NutriPals(TM) Peanut Butter Chocolate Bars in U.S., Mexico, New Zealand and Singapore
9. Abbott Receives FDA CLIA Waiver for Use of Five Additional Cartridges on the i-STAT Handheld Blood Analyzer
10. Rubicon Genomics Announces a Licensing Agreement With Abbott to Develop and Commercialize DNA Methylation Cancer Tests
11. Halo Pharmaceutical, Inc. Acquires Whippany Manufacturing Facility from Abbott
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/26/2017)... MO (PRWEB) , ... September 26, 2017 , ... ... agreement for patient scales with Premier Inc. Effective October 1, 2017, the new ... and terms pre-negotiated by Premier for patient scales. , “DETECTO is pleased to ...
(Date:9/26/2017)... ... ... the Millennium”: a gripping take on how the author used personal experience to strengthen ... and do not affect daily choices. It shows how to act like the heirs ... are chosen. “How to Live in the Millennium” is the creation of published author, ...
(Date:9/26/2017)... ... ... “The Ballad of Cowboy Justin”: a charming tale of a brave cowboy who ... creation of published author, Leah Westbrook, a wife and mother who loves to spend ... a delightful tale about a young brave cowboy, Cowboy Justin, who saves the town ...
(Date:9/26/2017)... ... September 26, 2017 , ... “Childhood Memories of a Virginia Wanderer”: ... and help them relive their own youth. “Childhood Memories of a Virginia Wanderer” is ... US Navy for nine years. He received his BS from Idaho State University ...
(Date:9/26/2017)... ... September 26, 2017 , ... “The Tour Guide”: is the life story of the ... creation of published author, David Alexander Stark, is an adventure tour guide and the subject ... around to the back to confront fifteen shocked faces. I played it off as a ...
Breaking Medicine News(10 mins):
(Date:9/25/2017)...   Montrium , an industry leader in ... IQPC Trial Master Files & Inspection Readiness Conference ... Clinical Services has selected eTMF Connect ... EastHORN, a leading European contract research organization (CRO), ... to enable greater collaboration with sponsors, improve compliance ...
(Date:9/25/2017)... , Sept. 25, 2017  EpiVax, Inc., a ... design, and immune-engineering today announced the launch of ... development of personalized therapeutic cancer vaccines. EpiVax has ... exclusive access to enabling technologies to the new ... will lead EpiVax Oncology as Chief Executive Officer. ...
(Date:9/23/2017)... , Sept. 22, 2017 Janssen Biotech, Inc. ... response letter from the U.S. Food and Drug Administration ... of sirukumab for the treatment of moderately to severely ... additional clinical data are needed to further evaluate the ... severely active RA. ...
Breaking Medicine Technology: